Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

Spanish Lung Cancer Library - Raez - Leading Treatment Options for Patients with Negative Tumor PD-L1 in 2020
dbrock
Spanish Lung Cancer Library -Raez- Opciones de Tratamiento, Pacientes con Cancer de Pulmon PD L1 Negativo
Author
Luis Raez, MD FACP FCCP
Image
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.

Para conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida en español para nuestra comunidad latina, el Dr. Luis E. Raez nos brinda la información más reciente sobre el cuidado del cáncer de pulmón.

En este video, el Dr. Raez analiza las principales opciones de tratamiento para pacientes con tumor negativo PD-L1 en 2020.

Para unirse a la conversación, visite https://cancergrace.org/forum.

*****

For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Luis E. Raez provides us with the latest information in lung cancer care.

In this video, Dr. Raez discusses the leading treatment options for patients with negative tumor PD-L1 in 2020.

 

To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise about appropriate treatment, "Right patient, right time, right team".

 

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Recent Comments

JOIN THE CONVERSATION
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on